Acutis at Industry events

Meet Acutis at the following events


May 13-14,


Tampa Bay Latin American Medical Society



May 6-7,


New York State Pain Society Annual Meeting 2022

Culinary Institute of America, Hyde Park, NY


October 29,


Richmond County Medical Society's Annual Past President's Dinner

Staten Island, NY


May 17-19,


New York State Pain Society Annual Meeting 2019

The Renaissance Westchester Hotel, West Harrison, NY


April 17-18,


Pri-Med, Washington, DC

Washington, DC

Ask us about having one of our
clinical toxicology or infectious disease specialists
speak at your event.

JSarij 6-web.jpg

Have Jibreel Sarij, CEO of Acutis

Jibreel is passionate about improving care with the convergence of science, technology, and service. He brings over two decades of global experience to Acutis as its founding CEO. His knowledge in the infectious disease, toxicology and oncology departments makes his insight valuable and inspiring.

As we look to the future, Acutis CEO Jibreel Sarij has this to say: “Acutis expects that gene sequencing will dramatically improve the way cancer medication is developed and that biomarker-specific treatment will be based on diagnostics, such as those being developed by Acutis.” 

dr-halim copy.jpg

Have Abdel Halim, Chief Scientific Officer, Biopharma & Diagnostic Service

Abdel Halim PharmD, MSc, PhD, DABCC, FAACC has joined as Chief Scientific Officer and Executive Vice President for biopharma and diagnostics services.  

Dr. Halim is a globally recognized expert in cancer molecular profiling, precision drug development, and diagnostic biomarker development with over 25 years of experience. One of only four laboratory scientists in the country to be triple board-certified, Dr. Halim is recognized by the medical community as well as regulators for his expertise and contributions to precision medicine and diagnostic development.  

-WEB-ig-UTI-industry-leading turnaround time copy 2.jpg

Have one of our clinical toxicology or infectious disease specialists

In addition to cancer treatment research, Acutis has responded to the opioid epidemic with specialized clinical toxicology testing for patients in substance use treatment. In 2019, the company introduced molecular testing with a focus on infectious disease, which proved timely when the Covid-19 pandemic hit. Acutis has performed more than 2.5 million Covid tests since March 2020.

Fill out the form below: